iX Syrinx is a member of the iX Biopharma Group (iX).

iX has a portfolio of products in the pipeline utilising our WaferiX^® sublingual delivery system.

Scientific Publications

• The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine  +

  Oxford Journal on Pain Medicine, 2017

• The Absolute Bioavailability of Racemic Ketamine from a Novel Sublingual Formulation +

  British Journal of Clinical Pharmacology, 2013

Australia Registered Medicines

• Wafesil (Sildenafil Citrate) Sublingual Wafers
  ARTG 288496, 288497
  Product Information +
  Consumer Medicine Information +
• Silcap (Sildenafil Citrate) Oral Capsules
  ARTG 291996, 29199
  Product Information +
  Consumer Medicine Information +
  

Supergenerics

WaferiX^® is a platform drug delivery technology which can be used to formulate off-patent generic drugs into a new dosage form with superior characteristics. These include improved absorption, faster onset of action and convenient administration. All of these provide market differentiation and prolong the product life cycle of off-patent drug.